Trial Profile
A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK0974 With Placebo for the Acute Treatment of Migraine With or Without Aura
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Telcagepant (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Chibret; Merck & Co; Merck Sharp & Dohme
- 21 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 23 Jun 2012 Additional locations added as reported by European Clinical Trials Database record.
- 23 Jun 2012 Planned number of patients changed from 1800 to 1834 as reported by European Clinical Trials Database record.